Abstract #3894

Improved the performance of differential diagnosis between Prostate Cancer and Benign Prostate Hyperplasia using APT and mDIXON-Quant

Xue Ren¹, Ailian Liu¹, Lihua Chen¹, Shuang Li¹, Yue Wang¹, Jiazheng Wang², Qingwei Song¹, Sun Peng², Renwang Pu³, and Yuanfei Li¹

¹The First Affiliated Hospital of Dalian Medical University, Dalian, China, ²Philips Healthcare, Beijing, China, ³First Affiliated Hospital of Dalian Medical University, Dalian, China

Accurate identifying prostate cancer (PC) from benign prostatic hyperplasia (BPH) is of great significance for timely and proper treatment. Amide proton transfer (APT) is a novel MRI method sensitive to several kinds of cancers. mDIXON-Quant is a powerful quantitive technique for simultaneous fat quantification and R2* mapping, which can reflect the tissue contents and properties. This study aims to assess the diagnostic performance of APT and mDIXON-Quant on differentiating prostate cancers and benign prostate hyperplasia. Results indicate that the combination of APT and mDIXON-Quant can enhance the differential diagnosis of PC and BPH.

This abstract and the presentation materials are available to members only; a login is required.

Join Here